A recombinant Semliki Forest virus particle vaccine encoding the prME and NS1 proteins of louping ill virus is effective in a sheep challenge model

Vaccine

Volumn 19, Issue 28-29, 2001, Pages 3877-3884

  Morris Downes, Margaret M ^a   Sheahan, Brian J ^b   Fleeton, Marina N ^c   Liljeström, Peter ^c,d   Reid, Hugh W ^e   Atkins, Gregory J ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c KAROLINSKA INSTITUTE   (Sweden)

^d SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^e MOREDUN RESEARCH INSTITUTE   (United Kingdom)

Author keywords

Biosafety; Louping ill virus; Recombinant vaccines; Semliki Forest virus

Indexed keywords

SEMLIKI FOREST VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFICACY; INFECTION PREVENTION; INJECTION SITE; LAMB; LYMPH NODE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEMLIKI FOREST ALPHAVIRUS; SHEEP DISEASE; TICK BORNE ENCEPHALITIS FLAVIVIRUS; VIRUS INFECTION;

ANIMALS; ANTIBODIES, VIRAL; BASE SEQUENCE; DNA PRIMERS; ENCEPHALITIS VIRUSES, TICK-BORNE; ENCEPHALITIS, TICK-BORNE; GENETIC VECTORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEMLIKI FOREST VIRUS; SHEEP; SHEEP DISEASES; VACCINES, SYNTHETIC; VIRAL NONSTRUCTURAL PROTEINS; VIRAL STRUCTURAL PROTEINS; VIRAL VACCINES;

EID: 0035898943     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00126-8     Document Type: Article

References (41)

1. Flaviviruses
2. Epidemiology of louping-ill
3. Louping-ill in man: A forgotten disease
4. Tracing the origins of louping ill virus by molecular phylogenetic analysis
5. Experimental louping-ill in sheep and lambs: Neuropathology
6. Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine
7. Elegantly presented DNA vaccines
8. Nonviral strategies for gene therapy
9. Exacerbation of viral and autoimmune animal models for multiple sclerosis by bacterial DNA
10. Induction of neonatal tolerance by plasmid DNA vaccination of mice
11. Do DNA vaccines induce autoimmune disease?
12. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle
13. Plasmid DNA malaria vaccine: Tissue distribution and safety studies in mice and rabbits
14. Semliki Forest virus-based vaccines: Persistence, distribution and pathological analysis in two animal systems
15. Sindbis virus: An efficient, broad host range vector for gene expression in animal cells
16. A new generation of animal cell expression vectors based on Semliki Forest virus replicon
17. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus - Expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo
18. Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles
19. Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus
20. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice
21. Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge
22. Flavivirus genome organization, expression, and replication
23. Recombinant vaccinia virus expressing PrM and E glycoproteins of louping ill virus: Induction of partial homologous and heterologous protection in mice
24. Evaluation of tick-borne encephalitis DNA vaccines in monkeys
25. High-level expression of the tick-borne encephalitis virus NS1 protein by using an adenovirus-based vector: Protection elicited in a murine model
26. Protection elicited by a replication-defective adenovirus vector expressing the tick-borne encephalitis virus non-structural glycoprotein NS1
27. Identification of naturally occurring monoclonal antibody escape variants of louping ill virus
28. Experimental louping-ill in sheep and lambs: Viraemia and the antibody response
29. Techniques for hemagglutination and hemagglutination-inhibition with anthropod-borne viruses
30. The Semliki Forest virus vector induces p53-independent apoptosis
31. Inhibition of human lung carcinoma cell growth by apoptosis induction using Semliki Forest virus recombinant particles
32. Immunological basis for protection in a murine model of tick-borne encephalitis by a recombinant adenovirus carrying the gene encoding the NS1 non-structural protein
33. Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge
34. High efficient induction of protective immunity by a vaccinia virus vector defective in late gene expression
35. Immunization with recombinant vaccinia viruses expressing structural and part of the non-structural region of tick-borne encephalitis virus cDNA protect mice against lethal encephalitis
36. Recombinant and virion-derived soluble and particulate immunogens for vaccination against tick-borne encephalitis
37. A DNA immunization model study with constructs expressing the tick-borne encephalitis virus envelope protein E in different physical forms
38. Two-helper RNA system for production of recombinant Semliki forest virus particles
39. Venezuelan equine encephalitis virus vaccines induce mucosal IgA responses and protection from airborne infection in BALB/c, but not C3H/HeN mice
40. Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate